Denali Therapeutics Inc. (DNLI)
DNLI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$18.40
-2.90% on the day
Market cap
$2.9B
Mid cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$512.5M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | DNLI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001714899 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$512.5M |
| Operating income | -$555.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $205.3M |
| Total assets | $1.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-10 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy DEFA14A ADDITIONAL MATERIALS | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 787 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.8% |
| 1 month | -13.3% |
| 3 months | -22.3% |
| Year to date | +7.0% |
| 1 year | +17.9% |
| From 52-week high | -35.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals Inc. | $70.82 | -4.81% | $3.3B |
| BEAM | Beam Therapeutics Inc. | $24.43 | -2.79% | $2.5B |
| ADMA | ADMA Biologics Inc | $10.31 | +1.28% | $2.3B |
| RLAY | Relay Therapeutics Inc. | $17.36 | -3.45% | $3.8B |
| ADPT | Adaptive Biotechnologies Corporation | $25.28 | -1.13% | $4.0B |
| NVAX | Novavax Inc. | $12.82 | +1.26% | $2.1B |
| ALVO | Alvotech | $5.38 | -2.18% | $2.1B |
| VCEL | Vericel Corporation | $40.30 | -0.79% | $2.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier